Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1938 1
1939 1
1940 2
1943 1
1949 5
1950 4
1951 2
1952 1
1953 2
1954 5
1955 3
1956 1
1957 5
1958 3
1959 6
1960 5
1961 4
1962 5
1963 6
1964 4
1965 4
1966 4
1967 4
1968 9
1969 5
1970 5
1971 5
1972 3
1973 2
1974 10
1975 6
1976 14
1977 10
1978 13
1979 11
1980 10
1981 11
1982 15
1983 21
1984 13
1985 18
1986 15
1987 16
1988 13
1989 29
1990 29
1991 20
1992 28
1993 22
1994 30
1995 24
1996 30
1997 22
1998 30
1999 34
2000 31
2001 25
2002 43
2003 41
2004 35
2005 33
2006 51
2007 56
2008 63
2009 62
2010 67
2011 80
2012 103
2013 86
2014 95
2015 95
2016 101
2017 89
2018 89
2019 100
2020 136
2021 138
2022 138
2023 145
2024 43

Text availability

Article attribute

Article type

Publication date

Search Results

2,334 results

Results by year

Filters applied: . Clear all
Page 1
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR; All ZUMA-7 Investigators and Contributing Kite Members. Locke FL, et al. Among authors: munoz j. N Engl J Med. 2022 Feb 17;386(7):640-654. doi: 10.1056/NEJMoa2116133. Epub 2021 Dec 11. N Engl J Med. 2022. PMID: 34891224 Clinical Trial.
Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity.
Marin I, Boix O, Garcia-Garijo A, Sirois I, Caballe A, Zarzuela E, Ruano I, Attolini CS, Prats N, López-Domínguez JA, Kovatcheva M, Garralda E, Muñoz J, Caron E, Abad M, Gros A, Pietrocola F, Serrano M. Marin I, et al. Among authors: munoz j. Cancer Discov. 2023 Feb 6;13(2):410-431. doi: 10.1158/2159-8290.CD-22-0523. Cancer Discov. 2023. PMID: 36302218 Free PMC article.
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy AH, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Bot AA, Shen RR, Dong J, Singh K, Miao H, Kim JJ, Zheng Y, Locke FL. Neelapu SS, et al. Among authors: munoz j. Blood. 2023 May 11;141(19):2307-2315. doi: 10.1182/blood.2022018893. Blood. 2023. PMID: 36821768 Free PMC article.
Macrophage Polarization and Osteoporosis: A Review.
Muñoz J, Akhavan NS, Mullins AP, Arjmandi BH. Muñoz J, et al. Nutrients. 2020 Sep 30;12(10):2999. doi: 10.3390/nu12102999. Nutrients. 2020. PMID: 33007863 Free PMC article. Review.
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS. Jacobson CA, et al. Among authors: munoz j. Lancet Oncol. 2022 Jan;23(1):91-103. doi: 10.1016/S1470-2045(21)00591-X. Epub 2021 Dec 8. Lancet Oncol. 2022. PMID: 34895487 Clinical Trial.
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM. Wang M, et al. Among authors: munoz j. J Clin Oncol. 2023 Jan 20;41(3):555-567. doi: 10.1200/JCO.21.02370. Epub 2022 Jun 4. J Clin Oncol. 2023. PMID: 35658525 Free PMC article.
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM. Wang M, et al. Among authors: munoz j. N Engl J Med. 2020 Apr 2;382(14):1331-1342. doi: 10.1056/NEJMoa1914347. N Engl J Med. 2020. PMID: 32242358 Free PMC article. Clinical Trial.
Structure of the RAF1-HSP90-CDC37 complex reveals the basis of RAF1 regulation.
García-Alonso S, Mesa P, Ovejero LP, Aizpurua G, Lechuga CG, Zarzuela E, Santiveri CM, Sanclemente M, Muñoz J, Musteanu M, Campos-Olivas R, Martínez-Torrecuadrada J, Barbacid M, Montoya G. García-Alonso S, et al. Among authors: munoz j. Mol Cell. 2022 Sep 15;82(18):3438-3452.e8. doi: 10.1016/j.molcel.2022.08.012. Epub 2022 Sep 1. Mol Cell. 2022. PMID: 36055235 Free article.
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial.
Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedell PA, Kekre N, de Vos S, Lui C, Milletti F, Dong J, Xu H, Chavez JC. Neelapu SS, et al. Among authors: munoz j. Nat Med. 2022 Apr;28(4):735-742. doi: 10.1038/s41591-022-01731-4. Epub 2022 Mar 21. Nat Med. 2022. PMID: 35314842 Free PMC article. Clinical Trial.
2,334 results